Literature DB >> 17277837

Relation between intracellular location and photodynamic efficacy of 5-aminolevulinic acid-induced protoporphyrin IX in vitro. Comparison between human glioblastoma cells and other cancer cell lines.

Reinhard Sailer1, Wolfgang S L Strauss, Michael Wagner, Helmut Emmert, Herbert Schneckenburger.   

Abstract

A promising clinical application of 5-aminolevulinic acid (5-ALA)-induced protoporphyrin IX (PP IX) is fluorescence detection and photodynamic treatment of residual tumour tissue during surgical resection of high grade malignant glioma. U373 MG human glioblastoma cells were used as a model system to study the relation between intracellular location and photodynamic efficacy of 5-ALA-induced PP IX in more detail. Therefore, ultra-sensitive fluorescence microscopy, using either optical excitation of whole cells or selective excitation of the plasma membrane by an evanescent electromagnetic field, was combined with quantitative measurements of intracellular porphyrin amount and phototoxicity. Glioblastoma cells accumulated PP IX to a moderate extent as compared to T47D breast cancer cells (high accumulation) or OV2774 ovarian cancer cells (low accumulation). Although photodynamic inactivation of the different cell lines (decreasing in the order T47D > U373 MG > OV2774) seemed to be directly related to PP IX accumulation, examination of the data in more detail revealed that photodynamic efficacy per photosensitizer molecule (PE) was about two times higher in glioblastoma and ovarian cancer cells as compared to breast cancer cells. The different photodynamic efficacy of PP IX was related to the different intracellular location. In contrast to breast cancer cells where PP IX fluorescence was localized in small granules, PP IX fluorescence in glioblastoma cells and ovarian cancer cells originated mainly from cellular membranes. Thus, the intracellular location of PP IX in a predominantly lipophilic environment, characterized by a comparably high photostability (probed by photobleaching and photoproduct formation) and a lower degree of porphyrin aggregation (probed previously by fluorescence decay kinetics), seems to be the key factor for high photodynamic efficacy of 5-ALA-induced PP IX. In the case of OV2774 ovarian cancer cells, however, a low PP IX accumulation limited cell inactivation upon irradiation, whereas the results obtained for glioblastoma cells are encouraging to develop PDT to an additional therapeutic option for the treatment of tumour margins in patients who underwent fluorescence-guided resection of high grade malignant glioma after 5-ALA administration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17277837     DOI: 10.1039/b611715e

Source DB:  PubMed          Journal:  Photochem Photobiol Sci        ISSN: 1474-905X            Impact factor:   3.982


  12 in total

1.  Matrix-dependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cells.

Authors:  Stephanie M Wittig-Blaich; Lukasz A Kacprzyk; Thorsten Eismann; Melanie Bewerunge-Hudler; Petra Kruse; Eva Winkler; Wolfgang S L Strauss; Raimund Hibst; Rudolf Steiner; Mark Schrader; Daniel Mertens; Holger Sültmann; Rainer Wittig
Journal:  Neoplasia       Date:  2011-07       Impact factor: 5.715

Review 2.  Structural and physico-chemical determinants of the interactions of macrocyclic photosensitizers with cells.

Authors:  Halina Mojzisova; Stéphanie Bonneau; Daniel Brault
Journal:  Eur Biophys J       Date:  2007-07-13       Impact factor: 1.733

3.  Preferential accumulation of 5-aminolevulinic acid-induced protoporphyrin IX in breast cancer: a comprehensive study on six breast cell lines with varying phenotypes.

Authors:  Stacy R Millon; Julie H Ostrander; Siavash Yazdanfar; J Quincy Brown; Janelle E Bender; Anita Rajeha; Nirmala Ramanujam
Journal:  J Biomed Opt       Date:  2010 Jan-Feb       Impact factor: 3.170

4.  Photodynamic therapy in combination with CO2 laser for the treatment of Bowen's disease.

Authors:  Hong Cai; Yi-xia Wang; Ji-Chun Zheng; Ping Sun; Zhi-yong Yang; Yuan-li Li; Xiao-yong Liu; Qiang Li; Wei Liu
Journal:  Lasers Med Sci       Date:  2015-04-22       Impact factor: 3.161

5.  5-ALA Fluorescence in Native Pituitary Adenoma Cell Lines: Resection Control and Basis for Photodynamic Therapy (PDT)?

Authors:  Andrei Nemes; Thomas Fortmann; Stephan Poeschke; Burkhard Greve; Daniel Prevedello; Antonio Santacroce; Walter Stummer; Volker Senner; Christian Ewelt
Journal:  PLoS One       Date:  2016-09-01       Impact factor: 3.240

Review 6.  Natural extracellular nanovesicles and photodynamic molecules: is there a future for drug delivery?

Authors:  Katsuyuki Kusuzaki; Takao Matsubara; Hiroaki Murata; Mariantonia Logozzi; Elisabetta Iessi; Rossella Di Raimo; Fabrizio Carta; Claudiu T Supuran; Stefano Fais
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

7.  Mechanistic study of PpIX accumulation using the JFCR39 cell panel revealed a role for dynamin 2-mediated exocytosis.

Authors:  Yuya Kitajima; Takuya Ishii; Takeo Kohda; Masahiro Ishizuka; Kanami Yamazaki; Yumiko Nishimura; Tohru Tanaka; Shingo Dan; Motowo Nakajima
Journal:  Sci Rep       Date:  2019-06-17       Impact factor: 4.379

8.  In vitro comparison of hypericin and 5-aminolevulinic acid-derived protoporphyrin IX for photodynamic inactivation of medulloblastoma cells.

Authors:  Rainer Ritz; Christian Scheidle; Susan Noell; Florian Roser; Martin Schenk; Klaus Dietz; Wolfgang S L Strauss
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

9.  A study of concentration changes of Protoporphyrin IX and Coproporphyrin III in mixed samples mimicking conditions inside cancer cells for Photodynamic Therapy.

Authors:  Rainer Landes; Alfredo Illanes; Daniela Goeppner; Harald Gollnick; Michael Friebe
Journal:  PLoS One       Date:  2018-08-31       Impact factor: 3.240

Review 10.  Systematic Review and Meta-Analysis of In Vitro Anti-Human Cancer Experiments Investigating the Use of 5-Aminolevulinic Acid (5-ALA) for Photodynamic Therapy.

Authors:  Yo Shinoda; Daitetsu Kato; Ryosuke Ando; Hikaru Endo; Tsutomu Takahashi; Yayoi Tsuneoka; Yasuyuki Fujiwara
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.